Compare Estee Lauder Companies Inc (EL) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Moderna, Inc. — how do they compare? Estee Lauder Companies Inc trades at $95.9 (market cap $34.17B), while Moderna, Inc. trades at $196.81 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 2.3× Estee Lauder Companies Inc's market cap, and Estee Lauder Companies Inc pays a 1.48% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 122 Days and Moderna, Inc. for 59 Days on average.
| EL | MRNA | |
|---|---|---|
Market Cap | $34.17B | $78.65B |
Volume | 3,921,497 | 37,373,437 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $203.46 |
52-Week Low | $67.23 | $22.36 |
Typical Hold Time | 122 Days | 59 Days |
Enterprise Value | $39.92B | $74.80B |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $94.45, up 1.17% with a bullish technical signal from moving averages. The company shows mixed fundamentals with a high P/E ratio of 188.9 but strong gross margins of 75.5%. Recent earnings beats in Q4 2025 and Q1 2026 contrast with a net loss of $1.13B in 2025. Analyst consensus is positive with 47.8% buy ratings and a $103 price target. Recent developments include AI partnerships and leadership changes.
Outlook remains cautiously optimistic as the company navigates profitability challenges while investing in digital transformation. Key opportunities include margin recovery and AI-driven growth initiatives, balanced against competitive pressures and execution risks in the beauty sector. The stock offers potential upside to analyst targets if turnaround efforts succeed.
Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.
Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
